Back to Newsroom
Back to Newsroom

H.C. Wainwright & Co. Initiates Coverage of GenSpera with a Buy Rating

Wednesday, 17 December 2014 12:00 PM

Topic:

New York, NY / ACCESSWIRE / December 17, 2014 / Market Exclusive announces that H.C. Wainwright & Co has initiated coverage with a Buy rating of GenSpera, Inc. (OTCQB: GNSZ) and a 12-month target price of $2.

According to the H.C Wainwrights & Co. report, "if successful, Genspera's platform could help provide a novel way to deliver drugs with higher efficiency to specific hard-to-treat cancers, such as HCC and GBM."

GenSpera, Inc., headquartered in San Antonio, Texas, is a biotechnology company specializing in the development of targeted prodrug agents for the treatment of various solid cancers.

About Market Exclusive

Market Exclusive is a financial portal geared to engaging discussion on current financial topics. Market Exclusive is not an investment advisor.

The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

 

SOURCE: Market Exclusive 

Topic:
Back to newsroom
Back to Newsroom
Share by: